Georgia Board of Public Health

October 11, 2022

Agenda

- Call to order
- Roll Call
- Approval/Adoption of Minutes
- New Business
 - Commissioner's Report
 - Georgia State Patrol Awards
 - Epidemiology Updates
 - COVID
 - Monkeypox
 - Monkeypox Vaccination
 - Rainbow Fentanyl
- Board Comments
- Adjournment

Commissioner's Report

Board of Public Health / Kathleen E. Toomey, M.D., M.P.H. / Oct. 11, 2022

Georgia State Patrol Awards and Recognition

In Recognition and Appreciation For your tireless support, collaboration, and leadership during the COVID-19 pandemic and beyond. Our Sincere Thanks and Gratitude **Colonel Chris C. Wright Lt. Colonel William W. Hitchens, III Georgia State Patrol**

Epidemiology Update

Board of Public Health / Cherie L. Drenzek, DVM, MS, State Epidemiologist / Oct. 11, 2022

Introduction

Infectious diseases are ever-changing and unpredictable!


Surveillance and epidemiologic investigation are the cornerstones of prevention and control recommendations.

Illustrated by: COVID and Monkeypox global outbreaks

COVID Snapshot (10-11-22): "BA.5 Receding, Others Rising?"

- The BA.5 subvariant is declining but still responsible for about 76% of all SARS-CoV-2 infections now.
- However, a trio of new Omicron subvariants are rising steadily (even tripling) in the last few weeks: **BA.4.6 (17%)**, and **BF.7 (4.4%)**, and **BA.2.75 (1.4%)**.
- In the US and Georgia, COVID case numbers have been **steadily decreasing** over the last several weeks, but we are seeing <u>increases in the Northeast</u>.
- Hospitalizations and deaths have also also have declined about 20% in the last two weeks (we are seeing just under100 deaths/week now)
- With new variants rising, caution and prevention aways remain prudent (including vaccination/bivalent boosters).


Total COVID-19 Cases




-80% decline since mid-August


COVID-19 Hospitalizations

Daily Counts of COVID-19 Patients




COVID-19 Deaths





Hospitalizations and Deaths by Vaccine Status




Summary: Pandemic is Not Over

- <u>Still no complacency</u>: SARS-CoV-2 is still with us, has proven very adept at changing, and still kills nearly 400 Americans per day (60% among those >70 years old).
- We should expect new variants and additional waves.
- <u>Other concerns</u>: waning immunity (>4 months), too few adults (and >12) getting bivalent boosters, too few kids getting vaccinated, and long COVID.
- Vaccination, boosters, antivirals, testing, and traditional mitigation are critical WHEN we face new variants that emerge and result in surges over the next several years.

Monkeypox Outbreak: Epidemiology

- Globally, since May, there have been about 70K monkeypox cases with 26K in the US alone
- Georgia has 1839 cases in 64 counties, but 85% of cases are in the metro Atlanta area.
- Case rates have been consistently slowing over the last few weeks nationally and in Georgia.

Monkeypox Epi Curve, Georgia



Monkeypox in Georgia: Epidemiology (cont'd)

- Gender of cases: 98% are male; 2% are female
- Vast majority of cases identify as MSM
- Age range of cases: 4-68 years, median: 34 years; 3 pediatric cases
- Race/Ethnicity (known for 95% cases): Vast majority **Black (79%) and Non-Hispanic (92%)**
- Main risk factor reported was close, sustained physical or sexual contact with someone who had monkeypox
- 5% of cases were hospitalized
- 60% of cases are HIV-positive and 42% had an STI in the past year
- Important data to inform interventions, vaccinations, and equity decisions

Severe Monkeypox Infections

- Although rare, severe manifestations of monkeypox can occur
- Limited data; few patients in US so far but increasing
- HIV+, severely immune compromised
- Atypical rash with coalescing or necrotic lesions
- Hallmark of **very rapid** deterioration
- Multiple organ system involvement (pulmonary, neuro, cardiac, ocular)
- Treatment: IV TPOXX, Vaccinia IGIV (limited data)
- Several fatal cases
- Underscores recommendation to test MPX patients for HIV, ensure ART, and to prioritize MPX vaccination HIV infected

https://emergency.cdc.gov/han/2022/han00475.asp

Closing Comments

- 1. Infectious diseases are ever-changing and unpredictable!
- 2. Surveillance and epidemiologic investigation are the cornerstones of prevention and control recommendations, including medical countermeasures for pre-and/or post-exposure prophylaxis.

Questions

For more information, please contact:

Cherie Drenzek, DVM, MS

State Epidemiologist & Chief Science Officer Georgia Department of Public Health (404) 657-2609 <u>cherie.drenzek@dph.ga.gov</u>

Monkeypox Vaccination

Board of Public Health / Alexander Millman, M.D., Chief Medical Officer / Oct. 11, 2022

Vaccine Availability

- Vaccines are being offered by appointments in all health districts
 - o <u>https://gta-vras.powerappsportals.us/en-US/</u>
 - Vaccine Scheduling Resource Line at (888) 457-0186
- Given the currently available supply, vaccine is being prioritized for specific indications
- As cases have declined and more people have been vaccinated, vaccine demand has begun to decline compared to earlier in the outbreak

Georgia MPX Vaccine Administration Data

As of October 5, 2022, there were 25,639 first dose recipients and 15,728 second dose recipients

Characteristic	First Dose Recipient	Second Dose Recipient
26-45 year age group	58%	58%
Male	94%	96%
Black or African American	45%	43%
Non-Hispanic	90%	91%

Data are updated weekly on Wednesdays: <u>https://dph.georgia.gov/monkeypox</u>


Current Vaccine Priorities (unchanged)

- Postexposure Prophylaxis (PEP)
 - $\circ~$ For high-risk exposure to a confirmed MPX case
 - Most beneficial when within 4 days of exposure but some may benefit up to 14 days following exposure
 - If given between 4–14 days after the date of exposure, vaccination may reduce the symptoms of disease, but may not prevent the disease.
- Expanded Postexposure Prophylaxis (PEP++)
 - For people with certain risk factors that might make them likely to have had high-risk exposure to someone with MPX
 - Used for response to outbreaks in areas where spread is occurring

Current Vaccine Priorities (new)

- Pre-exposure Prophylaxis (PrEP)
 - $\,\circ\,$ For vaccination before exposure to MPX
 - For people with certain occupational and sexual exposure risk factors that might make them likely to be exposed to MPX in the future
 - PrEP is also indicated for the sexual partners of those who meet eligibility criteria for PrEP and for people who anticipate experiencing those risk factors

MPX Vaccine Is Offering Protection From Infections



https://www.cdc.gov/mmwr/volumes/71/wr/mm7140e3.htm?s_cid=mm7140e3_w

Alternative Sites for Intradermal Administration

- Intradermal administration of vaccine is typically performed on the volar (inner aspect) of the forearm
- Some individuals who have received intradermal administration of MPX vaccine may have local reactions such as skin discoloration in the weeks to months after administration
- Intradermal administration may be performed at the upper back below the scapula or at the deltoid if the patient prefers an alternative site

Ongoing DPH Vaccine Efforts

- Broadened vaccine eligibility criteria to increase access to populations that may have higher likelihood of exposure to MPX
- Working with local health departments and community-based organizations for increasing uptake of first and second doses for eligible populations
- Being ready to respond to changes in outbreak epidemiology that may require re-evaluating vaccination priorities in the context of the currently limited supply of vaccine

COVID-19 Vaccine Updates

COVID-19 Bivalent Boosters

- Bivalent boosters are updated COVID-19 vaccines that protect against both the original virus and the Omicron BA.4/BA.5 variants
- Since August 31, bivalent formulations of the Pfizer (for 12 years and older) and the Moderna (for 18 years and older) COVID-19 vaccines have been authorized for use as a single booster dose at least 2 months after completion of a primary series
- For people who previously received a monovalent booster, the bivalent booster is administered at least 2 months after the last monovalent booster
- The bivalent booster is the only booster that can be used in the above populations
- Bivalent boosters can be co-administered with influenza vaccine. Now is a great time for people to get both vaccines if eligible

COVID-19 Bivalent Boosters

- As of 3pm on October 6, 2022, Georgia COVID-19 bivalent booster administration:
- Total Pfizer Bivalent Doses administered: 179,287
 - o 12-17 years: 6,713
 - o 18-64 years: 97,851
 - o 65+ years: 74,723

Total Moderna Bivalent Doses administered : 95,011

- o 18-64 years: 37,356
- o 65+ year: 57,655

On the Horizon

- Pfizer and Moderna have submitted data to FDA for pediatric bivalent boosters
- Pre-order period for Pfizer (5-11 years old) and Moderna (6-12 years old) pediatric bivalent boosters has ended.
 Pre-orders will ship after FDA has authorized use
- Anticipate FDA will be deciding on pediatric bivalent booster authorization soon

Questions

For more information, please contact:

Alex Millman, M.D. Chief Medical Officer Georgia Department of Public Health 404-463-6303 alexander.millman@dph.ga.gov

Rainbow Fentanyl

Board of Public Health / Amy Benson, MPA, ICPS / Oct. 11, 2022

Rainbow Fentanyl

- Brightly-colored fentanyl found in multiple forms (pills, powder, and blocks)
- Emerging trend across the United States
- In August 2022, DEA and law enforcement partners seized brightly-colored fentanyl and fentanyl pills in 18 states
- Recent DEA seizure in New York found 15,000 brightly colored pills containing fentanyl hidden in children's toys and appeared to be marketed as a party drug
- No seizures or reports in Georgia or our boarder states to date
 - Only purple substances or "purple heroin" has been seen in Georgia





Rainbow Fentanyl

Fentanyl Facts:


- Fentanyl is a synthetic opioid that is very potent – 2 mg of fentanyl (10-15 grains of tables salt) is considered a lethal dose
- Every color, shape, and size of fentanyl should be considered extremely dangerous
- Fentanyl is hidden in street drugs it can not be detected by sight or taste
- Illegally obtained drugs have a high potential to contain fentanyl
- Illicit drugs are often made to look like prescription drugs making it difficult to determine if legitimate or fake

Concerns:

- Fentanyl is deadly
- Colorful items appeal to adolescents
- Could appear as candy to a child
- Could be mistaken as a party drug/stimulant




Yearly Drug Overdose Deaths, By Drug Type, Georgia, January 2019 - December 2021



Source: Georgia Department of Public Health (DPH) Vital Records death certificates

Quarterly Fentanyl-Involved Overdose Deaths, Georgia, January 2019 - December 2021




Source: Georgia Department of Public Health (DPH) Vital Records death certificates

Drug Overdose Among Adolescents in Georgia

From 2019 to 2021, overdose deaths among adolescents (aged 10-19 years) increased 142%

 In 2021 alone, overdose deaths among adolescents increased 70%

 Fentanyl-involved overdose deaths increased at a faster rate among adolescents than adults (aged 20+ years)



Overdose Deaths Among Adolescents in Georgia


Drug Overdose Deaths Among Adolescents Ages 10-19 Years by Drug Type, Georgia, 2019 – 2021ª									
	20	19	2020		2021 ^b		% Change		
Drug Type	Ν	Rate	Ν	Rate	N	Rate	2019-2021		
Any Drug	19	1.30	27	1.85	46	3.07	142%		
Opioid	11	0.75	19	1.30	37	2.47	236%		
Fentanyl	4	0.27	14	0.96	36	2.40	800%		

^a Rates indicate the number of deaths per 100,000 population for 2019, 2020, and 2021.

^b 2021 counts are considered preliminary and subject to change as more deaths are certified.


Overdose Deaths Among Adolescents in Georgia

Overdose Deaths by Decedent Residence, Adolescents Aged 10-19 Years, Georgia, 2019-2021



DPH Efforts to Reduce Substance Use

- District Opioid Public Health Analysts (PHAs)
- Overdose Cluster Detection and Response
- Georgia Multi-Stakeholder Opioid and Substance Use Response Plan
- "Stop Overdose" Awareness Campaign
- Georgia Public Health Laboratory (GPHL) Toxicology Testing
- Increased access to naloxone and fentanyl test strips




Prevent Substance Use and Drug Overdoses

- Encourage parents and caregivers to talk with their children about substance use
- Support local prevention efforts in your community
- Recognize the signs of youth who may be at risk for drug use:
 Mood changes
 - $\circ~$ Poor class attendance, low grades, and/or behavior problems
 - Disregard for school rules
 - Memory lapses, poor concentration, bloodshot eyes, slurred speech
 - Switching friends and a reluctance to meet new friends
- Provide opportunities to educate and bring awareness to youth about the risks of hidden fentanyl in illicit drugs

Risk of Overdose

- Carry and be prepared to administer **naloxone** if you or someone you know is at risk
- Refer individuals to the Georgia Crisis & Access Line (GCLA) at 1-800-715-4225, available 24/7, for access to services and immediate crisis help
- Increase awareness and educate others of the risks associated with drug use, signs of an overdose, and how to respond



Questions

For more information, please contact:

Amy Benson Opioid and Substance Misuse Response Program Georgia Department of Public Health 470-725-5917 Amy.Benson1@dph.ga.gov

Next Meeting

The next Board of Public Health Meeting will be held Nov. 08, 2022